The
slide to be stained for GCDFP comprised:
1. Breast hyperplasia, 2. - 5. Breast ductal carcinomas.
All tissues were fixed in 10% neutral buffered formalin.
Criteria for assessing a GCDFP staining as optimal were:
- A strong, distinct cytoplasmic staining reaction in scattered ductal
epithelial cells and apocrine metaplastic cells of the hyperplastic breast.
- A moderate to strong, distinct cytoplasmic
staining reaction in the
majority of the neoplastic cells of the breast carcinomas no. 2, 4
and no. 5.
- At least a weak cytoplasmic and dot-like
staining reaction in scattered neoplastic cells of the breast carcinoma no. 3.
- No more than moderate background staining in the vicinity of the
positive cells. Background staining was accepted due to antigen diffusion.
Of 131 participating laboratories 86 % achieved a sufficient mark.
In table 1 the antibodies (Abs) used and marks are summarized.
Table 1.
Abs and
assessment marks
for GCD, run 36
|
Concentrated Abs |
N |
Vendor |
Optimal |
Good |
Borderl. |
Poor |
Suff.1 |
Suff. OPS2 |
|
mAb clone 23A3 |
43
12
10
2
2
1
1
1 |
Leica/Novocastra
Thermo/Neomarkers
Dako
Cell Marque
Diagnostic Biosystems
Labs Inc.
Vector Lab.
Abcam |
25 |
33 |
8 |
6 |
81 % |
88 % |
|
mAb clone D6 |
6
2
1
1
1 |
Covance/Signet
ID Labs
Biocare
Invitrogen
Sanbio |
4 |
5 |
1 |
1 |
82 % |
86 % |
|
mAb SPM135 |
1 |
Spring Bioscience |
0 |
1 |
0 |
0 |
- |
- |
|
rmAb EP1582Y |
2
1 |
Cell Marque
Zytomed systems |
1 |
2 |
0 |
0 |
- |
- |
|
rmAb EP95 |
1 |
Epitomics |
0 |
1 |
0 |
0 |
- |
- |
|
Ready-To-Use Abs |
|
|
|
|
|
|
|
|
mAb clone 23A3
IS/IR077 |
20 |
Dako |
10 |
10 |
0 |
0 |
100 % |
100 % |
mAb clone 23A3
PA0350 |
1 |
Leica/Novocastra |
0 |
1 |
0 |
0 |
- |
- |
mAb clone 23A3
257M-17 |
1 |
Cell Marque |
0 |
1 |
0 |
0 |
- |
- |
mAb clone 23A3
MS-1170 |
1 |
Thermo/Neomarkers |
0 |
0 |
1 |
0 |
- |
- |
mAb clone 23A3
MAD-001638QD |
1 |
Master Diagnostica |
0 |
0 |
1 |
0 |
- |
- |
rmAb clone
EP1582Y
760-4386 |
18 |
Ventana |
10 |
7 |
1 |
0 |
94 % |
94 % |
rmAb clone
EP1582Y
AN481-5M |
1 |
Biogenex |
0 |
1 |
0 |
0 |
- |
- |
|
Total |
131 |
|
50 |
62 |
12 |
7 |
|
|
|
Proportion |
|
|
38 % |
48 % |
9 % |
5 % |
86 % |
|
1) Proportion of sufficient stains
(optimal or good), 2) Proportion of sufficient stains with optimal
protocol settings only, see below.
Following protocol parameters were central to obtain an optimal
staining:
Concentrated Abs mAb clone 23A3: Protocols giving an optimal result were all based on
heat induced epitope retrieval (HIER) using either Target Retrieval
Solution pH 9 (3-in-1) (TRS pH 9;Dako) (8/18)*, Bond Epitope
Retrieval Solution 2 (BERS2; Leica) (6/9), Cell Conditioning 1
(CC1; Ventana) (8/25), Tris-EDTA/EGTA pH 9 (2/10) or Bond
Epitope Retrieval Solution 1 (BERS1; Leica) (1/3)as the
retrieval buffer. The mAb was typically diluted in the range of
1:10-1:75 depending on the total sensitivity of the protocol
employed. Using these protocol settings 30 of 34 (88 %) laboratories
produced a sufficient staining (optimal or good).
* (number of optimal results/number of laboratories using this
buffer)
mAb clone D6: Protocols giving an optimal result were all based on HIER using either Tris pH 9 (1/1), BERS2 (Bond, Leica) (1/1), CC1 ( Ventana) (1/1) or Tris-EDTA/EGTA pH 9 (1/1) as the retrieval buffer.
The mAb was typically diluted in the range of 1:4-1:100 depending on
the total sensitivity of the protocol employed. Using these protocol
settings 6 of 7 (86 %) laboratories produced a sufficient staining.
rmAb EP1582Y: Protocol giving an optimal result was based on HIER
with CC1 (Ventana) (1/1) as the retrieval buffer. The
rmAb was diluted 1:1.000 and OptiView (Ventana, 760-700) was used as
detection system.
Ready-To-Use Abs mAb clone 23A3 (product.no. IS / IR077, Dako): Protocols giving an
optimal result were based on HIER in PT-Link using TRS pH 9 (3-in-1)
or TRS pH 9 (heating time 10-30 min at 95-97°C), 20 min incubation
of the primary Ab and EnVision FLEX/FLEX+ (K8000/K8002) as detection
system. Using these protocol settings 20 of 20 (100 %) laboratories
produced a sufficient staining (optimal or good).
rmAb clone
EP1582Y (prod. no. 760-4386, Ventana): Protocols giving
an optimal result were all based on HIER using mild or standard CC1,
8-36 min incubation of the primary Ab and UltraView (760-500) or
OptiView (760-700) as detection system. Using these protocol
settings 15 of 16 (94 %) laboratories produced a sufficient staining
(optimal or good).
The most frequent causes of insufficient stains were:
- Too low concentration of the primary antibody - Use of low sensitive detection systems.
In concordance with the previous NordiQC assessment for GCDFP, the
prominent feature of an insufficient staining was a too weak or
false negative staining of structures expected to be demonstrated.
The majority of laboratories were able to demonstrate GCDFP in
apocrine metaplastic cells and the majority of neoplastic cells of
the breast carcinomas no. 2, 4 and 5. Demonstration of GCDFP in
normal ductal epithelial cells of the hyperplastic breast specimen
and in particular neoplastic cells of breast carcinoma no. 3 was
more challenging and required an optimally calibrated protocol.
A sufficient result (optimal or good) could be obtained with all the
clones used. In this assessment 126 of 131 participants used HIER.
49 of 50 optimal protocols were based on the use of an alkaline HIER
buffer. Applied as a concentrate with an in-house calibrated system,
the most widely used Abs were the mAb clones 23A3 and D6 showing a
relative high pass rate of 81% and 82%, respectively.
The proportion of sufficient results was influenced by the choice of
the detection system used. If the mAb clone 23A3 was used as a
concentrate and applied with a 2-step polymer-/multimer-based
detection system (EnVision FLEX (Dako) or UltraView (Ventana)), 74%
(28/38) of laboratories obtained a sufficient staining result, and
22 % were optimal. If same protocol settings were applied with a more
sensitive 3-step polymer-/multimer-based detection system (EnVision
FLEX+ (Dako), Bond Refine (Leica) or OptiView (Ventana)), 94 %
(29/31) of the laboratories obtained a sufficient
staining result and 55% obtained an optimal mark. Compared to the overall pass rate of 86%, the pass
rate was significant lower for the participants using a biotin based
detection systems, as 6 out of 10 laboratories obtained an
sufficient staining result (60%) out of which none was assessed as
optimal.
11 participants used the mAb clone D6 as a concentrate of which 3
protocols were based on proteolytic digestion and 2 protocols used
no pre-treatment at all. Of the protocols based on non-HIER, 4 out
of 5 laboratories produced a sufficient staining result (80%) but
none (0%) were assessed as optimal, as an excessive background
staining typically was seen compromising the interpretation. Of the
remaining 6 protocols, all based on HIER, 4 out of 6 laboratories
produced a sufficient staining result (67%) and all (100%) were
assessed as optimal. The slightly lower pass rate, compared to
participants using non-HIER, was caused by use of less sensitive
protocol settings as too low concentration of the primary Ab and/or
insufficient HIER.
The most successful and robust assay for GCDFP in this assessment
was obtained by the Dako RTU format based on mAb clone 23A3 (IS /
IR077) giving a pass rate of 100% (20/20) of which 50% were assessed
as optimal. The Ventana/Cell Marque RTU format based on rmAb clone EP1582Y
(760-4386) also provided a high pass rate of 94% (17/18) out of
which 53% (10/18) were assessed as optimal.
Controls Normal skin is the preferred positive control for GCDFP. The
epithelial cells of the eccrine sweat glands must show an as strong
as possible positive cytoplasmic staining reaction, while all other
cells should be negative. As in this assessment, normal breast
tissue can also be used as control in which scattered epithelial
cells of the ductal glands must show an as strong as possible
staining reaction. For both skin and breast tissue a weak to moderate background
staining in the vicinity of a strong staining reaction must be
accepted due to antigen diffusion – an aberrant nuclear staining
reaction in these areas may also be observed and has to be accepted.
It has to be emphasized that the number and intensity of the ductal
epithelial cells may vary throughout these two tissues.
Effect of external quality assessment
This was the second assessment of GCDFP in NordiQC. A significant
increase in the proportion of sufficient results was observed
compared to the previous run 25 (Table 2).
Table 2:
Proportion of sufficient results for GCDFP
| |
Run 25 2009 |
Run 36 2012 |
|
Participants, n= |
43 |
130 |
|
Sufficient results |
61 % |
87 % |
The pass rate of 87 % in this assessment was high and was obtained
despite many new laboratories participating for the first time. The
explanation could be due to several factors including extended use
of properly calibrated commercially available RTU formats or less
challenging tissue material circulated.
Conclusion The mAb clones
23A3, D6 and the rmAb clone EP1582Y are all
recommendable Abs for GCDFP. Efficient HIER in an alkaline buffer in
combination with a sensitive and specific IHC system is mandatory
for optimal performance. Biotin based detection systems can not be
recommended due to a reduced sensitivity and the risk of a false
positive staining reaction caused by endogenous biotin. In this
assessment the Ready-To-Use systems based on the mAb clone 23A3 from Dako and rmAb clone
EP1582Y from Ventana or Cell Marque gave the
highest proportion of sufficient results. Normal skin is an appropriate control: The epithelial cells of the
eccrine sweat glands must show the strongest possible cytoplasmic
reaction, while all other cells should be negative. A weak
background staining can be expected. |